Please indicate Initials and country e.g. MvD; Netherlands Date updated INTERDEM MEMBERS - BRIEF CURRICULUM VITAE Please can you complete this document and return to [email protected] Please can you also add PHOTO

NAME: Clive G Ballard

TITLE: Professor

PROFESSIONAL GROUPING  WORK ADDRESS: Wolfson Centre for Age-Related Diseases, Wolfson Wing, Guy’s Campus, King’s College London, London SE1 1UL, UK

TEL: +4420 7848 6568 FAX: +4420 7848 6816 EMAIL: [email protected] WEBLINK:

PRESENT POSITION e.g. Director of etc AND HIGHEST ACADEMIC QUALIFICATION e.g. PhD MD etc:

Professor of Age Related Disorders, Co-Director of Wolfson Centre for Age-Related Diseases, Co-Director Biomedical Research Unit – , Institute of /King’s College London; and Director of Research for the Alzheimer’s Society.

MB ChB, Leicester 1987, MRCPsych 1991, M.Med.Sci. 1992 . MD (Depression and Psychotic Symptoms in Dementia). University of Leicester 1995. Accredited higher training in old age psychiatry.

DESCRIPTION OF ORGANISATION

PREVIOUS EXPERIENCE OF THE CENTRE

PROFILE OF MEMBER

AREAS OF EXPERISE Please indicate Initials and country e.g. MvD; Netherlands Date updated

KEY PUBLICATIONS (maximum 5)

Owen AM et al (Ballard C senior author). Putting brain training to the test. Nature 2010; 465:775-78.

Ballard C, Hanney ML, Theodoulou M et al. The dementia withdrawal trial (DART- AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology 2009; 8:151-7.

Ballard CG, Gauthier S, Cummings JL et al. Management of agitation and aggression associated with Alzheimer disease. Nature Reviews Neurology 2009; 5: 245-55.

Fossey J, Ballard C, Juszczak E et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ 2006; 332:756-61.

Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nature Reviews Neuroscience 2006; 7: 492-500.

RELEVANT RESEARCH ACTIVITY Please indicate for past 5 years only (1) Grants Awarded: Names of Investigators; Years; Title of Project; name of awarding agency. (ii) PhD and other projects: Title; start or completed date

1. NIHR (Research for patient benefit). An intervention to reduce post-operative cognitive decline in older people undergoing cardiac surgery. (C Ballard, co-PI) 2010-2012 £110,000 2. Stroke Association/Alzheimer’s Society Prevention and post-stroke dementia. (C Ballard Co-PI) 2009-2012 £400,000 3. Stroke Association MR spectroscopy to identify progenitor cells after Stroke (C Ballard, Co- PI). 2010-2013 £100,000 4. Wellcome Trust Retinoic acid receptor alpha agonists for the treatment of Alzheimer’s disease. (C Ballard Co-Applicant) 2008-2011 £3,1m 5. Alzheimer’s Society Endogenous stem cells in and Alzheimer’s disease (C Ballard Lead Applicant) 2010-2012 £125,000 6. Medical Research Council Double blind clinical trial to examine Donepezil and Memantine in moderate to severe Alzheimer’s disease (DOMINO-AD). (C Ballard Co-PI) 2006- 2013 £2.5m 7. Dunhill Medical Trust Endogenous Progenitors in synuclein and impact of therapies (C Ballard Co-PI) 2008-2011 £100,000 8. Alzheimer’s Society/Alzheimer Research UK Brains for Dementia Research (coordination of 6 UK dementia brain banks) (C Ballard Co-PI) 2008-2013 £2.3m 9. Lundbeck Pharmaceutical Company Investigator led double blind RCT comparing memantine and atypical for the long term prophylaxis of neuropsychiatric symptoms in people with Alzheimer’s Disease. (C Ballard Lead PI) 2008-2012 £1.5m 10. Age UK Can enhancing endogenous neurogenesis improve outcome in Alzheimer transgenic mice (Fellowship, C Ballard – Supervisor) 2008-2011 £400,000

Please indicate Initials and country e.g. MvD; Netherlands Date updated

CURRENT RESEARCH INTERESTS/ONGOING PROJECT TITLE Current Research interests include optimising care home interventions to improve quality of life and more effectively treat behavioural and psychological symptoms in people with dementia, overall management behavioural and psychological symptoms, synuclein dementias and stem cell research.

1. NIHR Biomedical Research Unit 2012-2017 (C Ballard PI and co-Director) £4.5m 2. European Union IDEA programme to develop therapeutic stem cell technology. (C Ballard PI, lead PI Ulrich Pison) 2012 5.8m Euros 3. NIHR (PROGRAMME GRANT) An optimized intervention to reduce and treat behavioural symptoms in people with d ementia living in care homes. (C Ballard, Lead PI) 2010-2012 £2m 4. Safra Foundation Novel therapeutic approaches to Parkinson’s disease (C Ballard joint lead PI) 2011-2016 £1m